UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

How safe is the use of thiazolidinediones in clinical practice?

Expert opinion on drug safety, 2009-01, Vol.8 (1), p.15-32

2009

Volltextzugriff (PDF)

Effects of thyroid dysfunction on lipid profile

The open cardiovascular medicine journal, 2011, Vol.5 (1), p.76-84

2011

Volltextzugriff (PDF)

Statin-associated adverse effects beyond muscle and liver toxicity

Atherosclerosis, 2007-11, Vol.195 (1), p.7-16

2007

Volltextzugriff (PDF)

Ezetimibe-associated adverse effects: what the clinician needs to know

International journal of clinical practice (Esher), 2008-01, Vol.62 (1), p.88-96

2008

Volltextzugriff (PDF)

Diagnosis and management of the metabolic syndrome in obesity

Obesity reviews, 2005-11, Vol.6 (4), p.283-296

2005

Volltextzugriff (PDF)

Acute infection with Epstein–Barr virus is associated with atherogenic lipid changes

Atherosclerosis, 2010-10, Vol.212 (2), p.607-613

2010

Volltextzugriff (PDF)

Do statins have an antiarrhythmic activity?

Cardiovascular research, 2007-07, Vol.75 (1), p.10-20

2007

Volltextzugriff (PDF)

The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome

Atherosclerosis, 2007-08, Vol.193 (2), p.428-437

2007

Volltextzugriff (PDF)

Persistence of an atherogenic lipid profile after treatment of acute infection with brucella

Journal of lipid research, 2009-12, Vol.50 (12), p.2532-2539

2009

Volltextzugriff (PDF)

Statins: another class of antihypertensive agents?

Journal of human hypertension, 2006-05, Vol.20 (5), p.320-335

2006

Volltextzugriff (PDF)

Fibrate-associated adverse effects beyond muscle and liver toxicity

Current pharmaceutical design, 2008-02, Vol.14 (6), p.574-587

2008

Volltextzugriff (PDF)

Are the pleiotropic effects of telmisartan clinically relevant?

Current pharmaceutical design, 2009-08, Vol.15 (24), p.2815-2832

2009

Volltextzugriff (PDF)

Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia

International journal of clinical practice (Esher), 2013-05, Vol.67 (5), p.412-419

2013

Volltextzugriff (PDF)

Statins and solid organ transplantation

Current pharmaceutical design, 2006-12, Vol.12 (36), p.4771-4783

2006

Volltextzugriff (PDF)

Pleiotropic effects of thiazolidinediones

Expert opinion on pharmacotherapy, 2008-05, Vol.9 (7), p.1087-1108

2008

Volltextzugriff (PDF)

Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures

Current drug targets, 2006-02, Vol.7 (2), p.211-228

2006

Volltextzugriff (PDF)

effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome

Diabetes, obesity & metabolism, 2008-06, Vol.10 (6), p.476-483

2008

Volltextzugriff (PDF)

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study

Current medical research and opinion, 2005-12, Vol.21 (12), p.1997-2006

2005

Volltextzugriff (PDF)

A review of the metabolic effects of sibutramine

Current medical research and opinion, 2005-03, Vol.21 (3), p.457-466

2005

Volltextzugriff (PDF)

Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects

International journal of clinical practice (Esher), 2007-04, Vol.61 (4), p.545-551

2007

Volltextzugriff (PDF)

Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome

Current pharmaceutical design, 2009-10, Vol.15 (29), p.3446-3462

2009

Volltextzugriff (PDF)

l-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study

Lipids, 2017, Vol.52 (1), p.1-9

2017

Volltextzugriff (PDF)

Lysis syndrome during therapy of visceral leishmaniasis

Infection, 2012-04, Vol.40 (2), p.121-123

2012

Volltextzugriff (PDF)

Sibutramine-associated adverse effects: a practical guide for its safe use

Obesity reviews, 2008-07, Vol.9 (4), p.378-387

2008

Volltextzugriff (PDF)

Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes

Expert opinion on pharmacotherapy, 2008-07, Vol.9 (10), p.1705-1720

2008

Volltextzugriff (PDF)

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(103)
Mit Volltextzugriff
(96)

Publikationsform

Artikel
(115)
Berichte
(1)

Sprache

Englisch
(116)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(75)
Science & Technology
(75)
Humans
(71)
Male
(34)
Female
(32)
Middle Aged
(29)
Biological And Medical Sciences
(26)
Medical Sciences
(26)
Pharmacology & Pharmacy
(26)
Aged
(22)
Cardiovascular System & Cardiology
(20)
Risk Factors
(19)
Pharmacology. Drug Treatments
(16)
Adult
(14)
Cardiac & Cardiovascular Systems
(14)
Drug Therapy, Combination
(14)
Metabolic Syndrome
(14)
Hydroxymethylglutaryl-Coa Reductase Inhibitors - Therapeutic Use
(13)
Cardiovascular Diseases - Prevention & Control
(12)
General & Internal Medicine
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

How safe is the use of thiazolidinediones in clinical practice?

Effects of thyroid dysfunction on lipid profile

Statin-associated adverse effects beyond muscle and liver toxicity

Ezetimibe-associated adverse effects: what the clinician needs to know

Diagnosis and management of the metabolic syndrome in obesity

Acute infection with Epstein–Barr virus is associated with atherogenic lipid changes

Do statins have an antiarrhythmic activity?

The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome

Persistence of an atherogenic lipid profile after treatment of acute infection with brucella

Statins: another class of antihypertensive agents?

Fibrate-associated adverse effects beyond muscle and liver toxicity

Are the pleiotropic effects of telmisartan clinically relevant?

Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia

Statins and solid organ transplantation

Pleiotropic effects of thiazolidinediones

Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures

effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study

A review of the metabolic effects of sibutramine

Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects

Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome

l-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study

Lysis syndrome during therapy of visceral leishmaniasis

Sibutramine-associated adverse effects: a practical guide for its safe use

Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes

Suchergebnisse filtern